Relmada Therapeutics, Inc. (RLMD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 190.69M |
| Enterprise Value | 187.19M |
| P/E Ratio | -5.81 |
| PEG Ratio | -0.06 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 2.55 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -11.32 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
Profitability
| Profit Margin | 0 |
| Operating Margin | 0 |
AD
Management Effectiveness
| Return On Assets | -0.25 |
| Return On Equity | -0.71 |
Income Statement
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | 0 |
| EBITDA | -57.39M |
| Net Income | -57.39M |
| Diluted EPS | -1.45 |
Balance Sheet
| Total Cash | 233.96M |
| Total Cash/Share | 2.7 |
| Total Debt | 0 |
| Total Debt/Equity | 0 |
| Current Ratio | 18.26 |
| Book Value Per Share | 2.53 |
Price History
| 52-Week Change | 927.89 |
| 52-Week High | 8 |
| 52-Week Low | 0.55 |
| Moving Average 50 Days | 6.84 |
| Moving Average 200 Days | 4.96 |
Statistics
| Average Volume | 1.62M |
| Shares Outstanding | 104.89M |
| % Held by Institutions | 211.91 |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
| Last Split Date | September 30, 2019 |
AD
